Yuheng Pang, Runze Shi, Liujia Chan, Yu Lu, Di Zhu, Tong Liu, . . . Wenjing Wang. (2023). The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo. Elsevier.
Chicago Style (17th ed.) CitationYuheng Pang, Runze Shi, Liujia Chan, Yu Lu, Di Zhu, Tong Liu, Meisi Yan, Yuji Wang, and Wenjing Wang. The Combination of the HDAC1 Inhibitor SAHA and Doxorubicin Has Synergic Efficacy in Triple Negative Breast Cancer in Vivo. Elsevier, 2023.
MLA (9th ed.) CitationYuheng Pang, et al. The Combination of the HDAC1 Inhibitor SAHA and Doxorubicin Has Synergic Efficacy in Triple Negative Breast Cancer in Vivo. Elsevier, 2023.
Warning: These citations may not always be 100% accurate.